NV
Novo Ventures
Corporate VCActiveNovo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo
Bagsvrd, DenmarkFounded 2022
71
Investments
9
Exits
$1.8B
AUM
12.7%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Novo Ventures.
Investment Thesis & Strategy
Novo Ventures invests in various stages of companies within the asset management, fintech, and social sectors, seeking to support innovative companies with the potential for significant impact.
Investment Activity
Deals per year over the last 17 years
1
20060
20070
20080
20090
20100
20110
20122
20130
20142
20152
20162
20170
20180
20190
20202
20211
2022Portfolio Companies
Selected investments from their portfolio of 71 companies
V
Vibliome Therapeutics
Biotech · Series A, 2022
S
Shape Therapeutics
Biotech · Series A, 2021
C
Cimeon
Biotech · Series A, 2021
B
Biohaven Pharmaceutical
Biotech · Growth, 2017
X
Xeris Biopharma
Biotech · Growth, 2017
C
Calliditas Therapeutics
Biotech · Growth, 2016
I
Inivata
Biotech · Growth, 2016
O
ObsEva
Biotech · Growth, 2015
N
Nykode Therapeutics
Biotech · Growth, 2015
A
Avillion
Biotech · Growth, 2013
C
Chiasma
Biotech · Growth, 2013
S
Symphogen
Biotech · Growth, 2006
Notable Exits
CompanyTypeYearValue / Acquirer
SequenomAcquisition2016—
MedivationAcquisition2016$14B
PharmacyclicsAcquisition2015$21B
Alvine PharmaceuticalsAcquisition2013—
Portola PharmaceuticalsIPO2013—
Aragon PharmaceuticalsAcquisition2013$430M
Onyx PharmaceuticalsAcquisition2013$10.4B
ZymoGeneticsAcquisition2010$885M
Seattle GeneticsIPO2001—
Frequently Asked Questions
Novo Ventures focuses on Series A, Series B stage investments.